References
I-93

1. Jones S, Parini R, Harmatz P et al. The effect of idursulfase on growth in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS). *Molecular Genetics and Metabolism*. 2013;109(1):41-8.

2. Sohn Y, Cho S, Park S, et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome). *Orphanet Journal of Rare Diseases*. 2013;8:42.

3. Barbier A, Bielefeld B, Whiteman M, et al. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. *Molecular Genetics and Metabolism.* 2013;110(3):303-10.

4. Żuber, Z, Świątkowska A, Jurecka A, et al. The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II. *PLoS One.* 2014; 9(1):e85074.

5. Pano A, Barbier A, Bielefeld B, et al. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome). *Orphanet Journal of Rare Diseases.* 2015;10: 50.

6. Muenzer J, Hendriksz C, Fan Z, et al. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. *Genetic in Medicine*. 2015;36.

7. Tomanin R, Zanetti A, D'Avanzo F, et al. Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years. *Orphanet Journal of Rare Diseases*. 2014;9:129.

8. Giugliani R, Villarreal M, Valdez C, et al. Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America. *Genetics and Molecular Biology*. 2014;37(2): 315–329.

9. Giugliani R, Hwu W, Szymanska A, et al. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. *Genetics in Medicine*. 2014;16(6):435–441.

10. ELAPRASE® (idursulfase) [package insert]. Shire Human Genetic Therapies, Inc. Lexington, MA. 2006, Revised 06/2013.

11. Sestito S, Ceravolo F, Grisolia M, et al. Profile of idursulfase for the treatment of Hunter syndrome. *Research and Reports in Endocrine Disorders*. 2015;5:79-90.

12. Guffon N, Heron B, Chabrol B, et al. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: A retrospective observational study. *Orphanet Journal of Rare Diseases*. 2015;10:43.

13. Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. *J Clin Pharm Ther*. 2014;39(3):215-224.

14. Ceravolo F, Mascaro I, Sestito S, et al. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience. *Italian Journal of Pediatrics.* 2013;1-3.

15. Burton Bk and Whiteman AH. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS). *Mol Gen and Met.* 2011;113-120.

16. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.

17. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed September 2, 2017.

18. MCG™ Care Guidelines, 21st edition, 2017, Home Infusion Therapy, CMT: CMT-0009(SR).

19. MICROMEDEX®SOLUTIONS Compendia. 2017. Idursulfase.

20. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Idursulfase.